stockportfolio.pro
Stoke Therapeutics, Inc. (STOK)
Healthcare · Biotechnology · NasdaqGS
Stoke Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $12.40M | $8.78M | $36.55M | $184.42M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-12.52M | $-32.33M | $-52.24M | $-85.81M | $-101.07M | $-104.70M | $-88.98M | $-6.88M |
| Net margin | — | — | — | — | -814.7% | -1192.5% | -243.4% | -3.7% |
Source: Stoke Therapeutics, Inc. SEC filings (10-K).
What growth is priced into STOK stock?
At today's market cap of $1.80B, Stoke Therapeutics, Inc. is priced for free-cash-flow growth of about 17.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $44.91M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of Stoke Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track STOK in your portfolio →
Stoke Therapeutics, Inc. financial history by metric
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc. — frequently asked questions
What is Stoke Therapeutics, Inc.'s revenue?
Stoke Therapeutics, Inc. (STOK) reported revenue of $184.42M for fiscal year 2025, up 404.5% from the prior year, according to its SEC filings.
Is Stoke Therapeutics, Inc. profitable?
No — STOK reported a net loss of $-6.88M in fiscal 2025.
What is STOK's P/E ratio?
Stoke Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Stoke Therapeutics, Inc. have?
As of fiscal year 2025, STOK carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Stoke Therapeutics, Inc.'s market cap?
Stoke Therapeutics, Inc. (STOK) has a market capitalization of about $1.80B, based on the latest data in our nightly-refreshed cache.
When does Stoke Therapeutics, Inc.'s fiscal year end?
STOK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into STOK stock?
At today's market cap of $1.80B, Stoke Therapeutics, Inc. is priced for free-cash-flow growth of about 17.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $44.91M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Stoke Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.